Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current Assets:    
Cash and cash equivalents $ 13,376 $ 19,055
Prepaid expenses and other current assets 1,540 2,515
Total Current Assets 14,916 21,570
Property and equipment, net 800 905
Deposits and other assets 24 23
Total Assets 15,740 22,498
Current Liabilities:    
Accounts payable 1,723 1,993
Accrued expenses 1,750 2,627
Warrant liabilities 7,573 14,821
Accrued employee benefits 1,209 313
Deferred rent 75 3
Total Current Liabilities 12,330 19,757
Long term deferred rent 448 492
Total Liabilities 12,778 20,249
Stockholders’ Equity:    
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.001 par value; 250,000,000 shares authorized, 127,827,578 issued and 127,746,096 outstanding and 117,254,196 issued and 117,172,714 outstanding 128 117
Additional paid-in capital 183,837 175,762
Accumulated deficit (179,135) (172,034)
Total Synthetic Biologics, Inc. and Subsidiaries Equity 4,830 3,845
Non-controlling interest (1,868) (1,596)
Total Stockholders' Equity 2,962 2,249
Total Liabilities and Stockholders' Equity $ 15,740 $ 22,498